Show simple item record

dc.contributor.authorCarey, Jennifer L.
dc.contributor.authorNader, Nathalie
dc.contributor.authorChai, Peter R.
dc.contributor.authorCarreiro, Stephanie
dc.contributor.authorGriswold, Matthew K.
dc.contributor.authorBoyle, Katherine L.
dc.date2022-08-11T08:08:18.000
dc.date.accessioned2022-08-23T15:49:53Z
dc.date.available2022-08-23T15:49:53Z
dc.date.issued2017-01-01
dc.date.submitted2017-10-24
dc.identifier.citation<p>Clin Ther. 2017 Jan;39(1):10-22. doi: 10.1016/j.clinthera.2016.12.009. Epub 2017 Jan 7. <a href="https://doi.org/10.1016/j.clinthera.2016.12.009">Link to article on publisher's site</a></p>
dc.identifier.issn0149-2918 (Linking)
dc.identifier.doi10.1016/j.clinthera.2016.12.009
dc.identifier.pmid28069260
dc.identifier.urihttp://hdl.handle.net/20.500.14038/28543
dc.description.abstractA large number of medications and medical devices removed from the market by the US Food and Drug Administration over the past 4 decades specifically posed greater health risks to women. This article reviews the historical background of sex and gender in clinical research policy and describes several approved drugs and devices targeted for use in women that have caused major morbidity and mortality. The intended population for the medications and devices, population affected, approval process, and the basic and legal actions taken against the medication/drug company are also discussed. It is recognized that women are still at risk for harm from unsafe medications and devices, and continued improvements in legislation that promotes inclusion of sex and gender into the design and analysis of research will improve safety for both men and women.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=28069260&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1016/j.clinthera.2016.12.009
dc.subjectmedication and device safety
dc.subjectsex and gender
dc.subjectUMCCTS funding
dc.subjectAnalytical, Diagnostic and Therapeutic Techniques and Equipment
dc.subjectWomen's Health
dc.titleDrugs and Medical Devices: Adverse Events and the Impact on Women's Health
dc.typeJournal Article
dc.source.journaltitleClinical therapeutics
dc.source.volume39
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/emed_pp/86
dc.identifier.contextkey10942883
html.description.abstract<p>A large number of medications and medical devices removed from the market by the US Food and Drug Administration over the past 4 decades specifically posed greater health risks to women. This article reviews the historical background of sex and gender in clinical research policy and describes several approved drugs and devices targeted for use in women that have caused major morbidity and mortality. The intended population for the medications and devices, population affected, approval process, and the basic and legal actions taken against the medication/drug company are also discussed. It is recognized that women are still at risk for harm from unsafe medications and devices, and continued improvements in legislation that promotes inclusion of sex and gender into the design and analysis of research will improve safety for both men and women.</p>
dc.identifier.submissionpathemed_pp/86
dc.contributor.departmentDepartment of Emergency Medicine, Division of Medical Toxicology
dc.source.pages10-22


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record